Trial reportThe Journal of investigative dermatology2015
Potential of Systemic Allogeneic Mesenchymal Stromal Cell Therapy for Children with Recessive Dystrophic Epidermolysis Bullosa.
Abstract readClinical TrialLetter
In one paragraph
Trial report in The Journal of investigative dermatology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 72 papers.
0numbers the graph read from it
0cells of the map it votes in
72citing papers in PubMed
6.5field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
72 citing papers in PubMed, 183 citations in OpenAlex.
- Mesenchymal stromal cell infusions of umbilical cord-derived mesenchymal stromal cells in children with Recessive Dystrophic Epidermolysis Bullosa (MissionEB): a qualitative sub study of a randomised, double-blind, placebo controlled, crossover, phase 3 trial.Orphanet journal of rare diseases · 2026Trial
- MesenSistem-EB: systemic haploidentical mesenchymal stem cell therapy in recessive dystrophic epidermolysis bullosa associated with clinical benefits and correlated with MCP1 and sCD40L dynamics.Frontiers in immunology · 2026Trial
- Intravenous allogeneic multilineage-differentiating stress-enduring cells in adults with dystrophic epidermolysis bullosa: a phase 1/2 open-label study.Journal of the European Academy of Dermatology and Venereology : JEADV · 2021Trial
- Intravenous allogeneic umbilical cord blood-derived mesenchymal stem cell therapy in recessive dystrophic epidermolysis bullosa patients.JCI insight · 2021Trial
- Identification of a long-term surviving human mesenchymal stromal cell subpopulation and implications for recessive dystrophic epidermolysis bullosa treatment.Stem cell research & therapy · 2026Article
- Utilization of Stem Cells in Medicine: A Narrative Review.International journal of molecular sciences · 2025Review
- Article
- Article
- Progress in skin gene therapy: From the inside and out.Molecular therapy : the journal of the American Society of Gene Therapy · 2025Review
- Mesenchymal stromal cell therapy in epidermolysis bullosa: current perspectives and future directions.Frontiers in cell and developmental biology · 2025Review
- Human urine-derived stem cells rescue cutaneous manifestation and suppress inflammation and fibrosisBurns & trauma · 2025Article
- Twin Prime Editing Mediated Exon Skipping/Reinsertion for Restored Collagen VII Expression in Recessive Dystrophic Epidermolysis Bullosa.The Journal of investigative dermatology · 2024Article
- Gene-edited cells: novel allogeneic gene/cell therapy for epidermolysis bullosa.Journal of applied genetics · 2024Review
- Systemic treatment of recessive dystrophic epidermolysis bullosa with mesenchymal stromal cells: a scoping review of the literature and conclusions for future clinical research.The Journal of dermatological treatment · 2024Article
- Safety and tolerability of losartan to treat recessive dystrophic epidermolysis bullosa in children (REFLECT): an open-label, single-arm, phase 1/2 trial.EClinicalMedicine · 2024Article
- Current Status of Biomedical Products for Gene and Cell Therapy of Recessive Dystrophic Epidermolysis Bullosa.International journal of molecular sciences · 2024Review
- Advances in Treatments for Epidermolysis Bullosa (EB): Emphasis on Stem Cell-Based Therapy.Stem cell reviews and reports · 2024Review
- Donor Muse Cell Treatment Without HLA-Matching Tests and Immunosuppressant Treatment.Stem cells translational medicine · 2024Review
- Revolutionizing dermatology: harnessing mesenchymal stem/stromal cells and exosomes in 3D platform for skin regeneration.Archives of dermatological research · 2024Review
- Emerging Gene Therapeutics for Epidermolysis Bullosa under Development.International journal of molecular sciences · 2024Review
12 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 6 institutions in 3 countries.
Gabriela PetrofSt John's Institute of Dermatology, King's College London (Guy's Campus), London, UK. Electronic address: john.mcgrath@kcl.ac.uk.
Su M LwinSt John's Institute of Dermatology, King's College London (Guy's Campus), London, UK.
Magdalena Martinez-QueipoSt John's Institute of Dermatology, King's College London (Guy's Campus), London, UK.
Alya Abdul-WahabSt John's Institute of Dermatology, King's College London (Guy's Campus), London, UK.
Simon TsoSt John's Institute of Dermatology, King's College London (Guy's Campus), London, UK.
Jemima E MellerioSt John's Institute of Dermatology, King's College London (Guy's Campus), London, UK; Department of Dermatology, Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK.
Ineke Slaper-CortenbachCell Therapy Facility, Department of Clinical Pharmacology, University Medical Centre Utrecht, Utrecht, The Netherlands.
Jaap J BoelensDepartment of Pediatrics, Blood and Marrow Transplantation Program, Wilhelmina Children's Hospital, University Medical Centre Utrecht, Utrecht, The Netherlands.
Jakub TolarDepartment of Pediatrics, Blood and Marrow Transplant, Medical School, University of Minnesota, Minneapolis, Minnesota, USA; Stem Cell Institute, University of Minnesota, Minneapolis, Minnesota, USA.
Paul VeysBlood and Marrow Transplantation Department, Great Ormond Street Hospital, London, UK.
Mercy OfuyaDivision of Health and Social Care Research, King's College London, London, UK.
Janet L PeacockDivision of Health and Social Care Research, King's College London, London, UK.
Anna E MartinezDepartment of Dermatology, Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK.
John A McGrathSt John's Institute of Dermatology, King's College London (Guy's Campus), London, UK.
King's College London · GBGreat Ormond Street Hospital · GBGreat Ormond Street Hospital for Children NHS Foundation Trust · GBUniversity Medical Center Utrecht · NLUniversity of Minnesota · USWilhelmina Children's Hospital · NL
Funding
Skin-targeted Cell Therapy for Recessive Dystrophic Epidermolysis BullosaR01AR063070 · NIAMS · UNIVERSITY OF MINNESOTA · PI Mark J Osborn, Jakub Tolar · 2013 to 2026
$4.5MNIAMS NIH HHS R01 AR063070
Abstract
PubMed holds no abstract for this paper.
Indexed as
ChildChild, PreschoolEpidermolysis Bullosa DystrophicaFemaleFollow-Up StudiesHumansMaleMesenchymal Stem Cell TransplantationProspective StudiesTransplantation, HomologousTreatment Outcome
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.